Everest Medicines’ EVER001 shows promising Phase 1b/2a trial results for autoimmune kidney disease treatment
Everest Medicines has announced promising preliminary results from its ongoing Phase 1b/2a clinical trial of EVER001, a next-generation Bruton's tyrosine kinase (BTK) inhibitor, for the ... Read More
Novartis’ atrasentan shows significant reduction in proteinuria in seasonal allergic rhinitis patients
Novartis presented compelling interim results from the Phase III ALIGN study evaluating the efficacy of atrasentan, an investigational oral selective endothelin A (ETA) receptor antagonist, ... Read More
Novartis reports significant proteinuria reduction by Fabhalta in Phase 3 IgAN trial
Novartis has shared encouraging results from the Phase III APPLAUSE-IgAN study, revealing that Fabhalta (iptacopan) led to a significant 38.3% reduction in proteinuria, as measured ... Read More
Novartis reveals significant results for Fabhalta in IgAN study at World Congress of Nephrology
Novartis has achieved a major milestone in the treatment of IgA nephropathy (IgAN), reporting a 38.3% reduction in proteinuria in a pivotal Phase III trial. ... Read More